Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
CONFIDENTIAL 1
ISO 20069Assessment & Evaluation of Changes to Drug Delivery Systems
Paul Jansen, PEChair Elect ISO TC84Board Member & Senior Advisor, HaselmeierBoard Member, Subcuject
CONFIDENTIAL 2
Drug Delivery Combination (DDC) products require assessment & evaluation when drug and device changes are proposed.
There is significant variability as to how companies manage those changes.
It is proposed to adopt a common framework for assessing & evaluating changes.
The framework of an ISO standard will be based upon a risk based approach.
CONFIDENTIAL
ISO 20069 is Here
3
CONFIDENTIAL
2010 IPAC-RS/ISAM workshop Frankfurt
4
CONFIDENTIAL
http://ipacrs.org/assets/uploads/outputs/Track_D.pdf
5
CONFIDENTIAL 6
Significant variability as to how companies manage changesRisk Management does not appear to be informing decision making.
Formulation & viscosity changes
7
Colour change
8
Process changes• Manual to automatic• Glue to sonic welding
9
Single Cavity mold to Multiple Cavity
10
User interface change
11
Assess & Evaluate impact:
Changes related to:
Medicinal productcomponent Device component
Medicinal productcomponent
x
Out of scope
In scope
Device component In scope
In scope
CONFIDENTIAL
-
13
Drug changes impacting device vs Device changes impacting drug
……….. It is the responsibility of organizations to provide evidence that the approach adopted is commensurate with the level of risk so as to ensure the quality, safety and effectiveness of the drug delivery system. While the focus of this document is change to the drug delivery system, it is also possible that changes to the medicinal product might impact the drug delivery system (e.g. change in viscosity or volume of medicinal product resulting in changed drug delivery system performance. It is also possible that changes to the drug delivery system might impact the medicinal product (e.g., increased injection forces resulting in changed medicinal product quality). …………
14
CONFIDENTIAL
- To be clear and concise
- To be descriptive not descriptive
- Global
- Gain good regulatory inputs
- Achieve consensus (always an ISO challenge!)
- Align with other documents – ie. ICH Q12
15
CONFIDENTIAL 16
ISO 20069 & ICH Q12 Alignment
ISO 20069
What and how Device assessment & evaluation - not drug/biologic Risk based assessment Focus on using prior knowledge Does not provide scope as it relates to a regulatory
submission
ICH Q12
Provides guidance on what to submit (or if to submit)
ICH Q12 complements ISO 20069
CONFIDENTIAL 17
- Issue Draft International Standard (DIS) – June 2018
- Public Enquiry – June to September 2018
- ISO WG15 Committee Meeting – October 2018
- Issue Final Draft International Standard (FDIS) - 2019
Paul Jansen, PEISO TC 84 Chair Elect
Board Member & Senior Advisor, Haselmeier
[email protected]+1 857 203 1470
18
Would you like to talk?